Radcliffe Capital Management, L.P. - IBERE PHARMACEUTICALS ownership

IBERE PHARMACEUTICALS's ticker is IBER and the CUSIP is G46843101. A total of 1 filers reported holding IBERE PHARMACEUTICALS in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Radcliffe Capital Management, L.P. ownership history of IBERE PHARMACEUTICALS
ValueSharesWeighting
Q4 2022$3,300,944
+1.8%
327,1500.0%0.10%
+33.3%
Q3 2022$3,242,000
+10.2%
327,150
+9.0%
0.08%
+14.7%
Q2 2022$2,943,0000.0%300,0000.0%0.07%
+1.5%
Q1 2022$2,943,000
+1.1%
300,0000.0%0.07%
-11.8%
Q4 2021$2,910,000
+0.1%
300,0000.0%0.08%
-10.6%
Q3 2021$2,907,000
+0.2%
300,0000.0%0.08%
-6.6%
Q2 2021$2,901,000300,0000.09%
Other shareholders
IBERE PHARMACEUTICALS shareholders Q3 2023
NameSharesValueWeighting ↓
Ampfield Management, L.P. 44,543$431,0000.35%
MANGROVE PARTNERS IM, LLC 200,000$1,934,0000.20%
SPRING CREEK CAPITAL LLC 400,000$3,868,0000.19%
Vestcor Inc 400,000$3,868,0000.13%
KNOTT DAVID M 36,000$348,0000.12%
Radcliffe Capital Management, L.P. 300,000$2,901,0000.09%
Hudson Bay Capital Management LP 621,750$6,012,0000.07%
BERKLEY W R CORP 68,776$666,0000.07%
PICTON MAHONEY ASSET MANAGEMENT 200,000$1,934,0000.06%
Polar Asset Management Partners Inc. 500,000$4,835,0000.05%
View complete list of IBERE PHARMACEUTICALS shareholders